Huguet Jorge, Musquera Mireia, Ribal Maria Jose, Alcaraz Antonio
Servicio de Urología. Hospital Clínic. Barcelona. España.
Arch Esp Urol. 2014 Jun;67(5):509-13.
In a context where there is evidence that not every patient with low risk prostate cancer needs to be treated from the start, active treatments are expensive and public health care systems need to save money, studies on cost-effectiveness are a priority. To elaborate this article, we reviewed the publications on cost and cost-effectiveness of localized prostate cancer treatments that include active surveillance. In patients with low risk localized prostate cancer active surveillance is more cost-effective than active treatment. With time active surveillance may be more expensive than brachytherapy or radical prostatectomy. The frequency of prostatic biopsies and the percentage of conversions to active treatment will be determinant in final costs of active surveillance.
在有证据表明并非每例低风险前列腺癌患者都需要从一开始就接受治疗、积极治疗费用高昂且公共卫生保健系统需要节省资金的背景下，成本效益研究成为当务之急。为撰写本文，我们回顾了有关包括主动监测在内的局限性前列腺癌治疗的成本及成本效益的出版物。对于低风险局限性前列腺癌患者，主动监测比积极治疗更具成本效益。随着时间推移，主动监测可能比近距离放射治疗或根治性前列腺切除术更昂贵。前列腺活检的频率以及转为积极治疗的比例将决定主动监测的最终成本。
